Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The hepatitis C revolution part 2: difficult-to-treat groups and experimental approaches.

Current opinion in infectious diseases - 1 Dec 2015

Thiagarajan Prarthana, Ryder Stephen D

Abstract excerpt

PURPOSE OF REVIEW: Novel direct-acting antiviral (DAA) agents are highly effective in the treatment of hepatitis C, achieving unprecedented rates of sustained virological response, a functional cure. However, a significant minority of patients belong to 'difficult-to-treat' groups, in which efficacy of DAAs appears less robust. The review article aims to discuss additional treatment strategies which may be...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzimidazoles
Share to Coinfection
Share to Drug Design

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Viral

Share to Fluorenes

Share to Hepatitis C

Share to Sofosbuvir

Share to Uridine Monophosphate

Source

Identifiers

PMID: 26524329
DOI: 10.1097/QCO.0000000000000204

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The hepatitis C revolution part 2: difficult-to-treat groups and experimental approaches.PMID 26524329Read ↗

The hepatitis C revolution part 1: antiviral treatment options.Semantic proximity Read ↗

Direct-acting antivirals: the endgame for hepatitis C?Semantic proximity Read ↗

Closing the Gap: The Challenges of Treating Hepatitis C Virus Genotype 3 Infection.Semantic proximity Read ↗

Genotype 3-hepatitis C virus' last line of defense.Semantic proximity Read ↗

Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis C.Semantic proximity Read ↗

The rapid evolution of treatment strategies for hepatitis C.Semantic proximity Read ↗

Are There Still Difficult-to-Treat Patients with Chronic Hepatitis C in the Era of Direct-Acting Antivirals?Semantic proximity Read ↗

Hepatitis C: clinical management and debated issues.Semantic proximity Read ↗

Treatment of hepatitis C in patients with cirrhosis: remaining challenges for direct-acting antiviral therapy.Semantic proximity Read ↗

Emerging therapies for hepatitis C virus.Semantic proximity Read ↗

Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection.Semantic proximity Read ↗

Revolution in hepatitis C antiviral therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.